TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30517723
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 500 mL beer
Study: 30517723
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 500 mL soda
Study: 30517723
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 500 mL beer and soda
Study: 27005463
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg anamorelin
Study: 27005463
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg anamorelin
Study: 24886581
Drug: Early specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early specific cognitive-behavioural psychotherapy (CBT) including stress management and problem solving strategies, with elements of mindfulness-based therapy (MBT) for 14 weeks.
Study: 16053475
Drug: subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous interferon (IFN) beta‐1a, 22 or 44 mug three times weekly
Study: 11834004
Drug: Diuretics (fusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (fusemide and amiloride)
Study: 1819543
Drug: Lisuride (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (0.1 mg, 1/2 tablet every 8 hours for 3 months)
Study: 6128451
Drug: Increased oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased oral potassium 64 mmol a day
Study: 25207682
Drug: Intravenous lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lipid emulsion (20% Intralipid®)
Study: 22526529
Drug: Triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25 and 0.5 mg/70 kg)
Study: 19106243
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (20 g protein/session) before and after exercise
Study: 12495901
Drug: rHuG-CSF 10
Normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rHuG-CSF 10 mg/kg
Study: 9667102
Drug: KH 1060
Normalized name: KH-176
DrugBank: Sonlicromanol (DB16333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KH 1060 ointment
Study: 11316966
Drug: Ebastine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine (10 mg)
Study: 31376781
Drug: Question Formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Question Formulation Technique (QFT) intervention
Study: 27126336
Drug: Ectoine mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ectoine mouth and throat spray
Study: 27126336
Drug: Saline lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline lozenges
Study: 20456625
Drug: Traditional sex
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional sex therapy and/or gingko biloba
Study: 15760426
Drug: Antifungal therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal therapy for 2 weeks and 3 months
Study: 15760426
Drug: Anti-retroviral agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-retroviral agents
Study: 9045329
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 and paclitaxel 135 mg/m2
Study: 9045329
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 and cyclophosphamide 750 mg/m2
Study: 31617769
Drug: Paracetamol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol administration by parents after GP consultation
Study: 31617769
Drug: Paracetamol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol administration in children aged three to six months
Study: 31617769
Drug: Paracetamol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol administration in children aged five to twelve years
Study: 31617769
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of paracetamol administration for common infections
Study: 29402561
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of the implant
Study: 29402561
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading of the implant
Study: 26659706
Drug: BOC add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOC add-on therapy at week 12 for patients without cEVR
Study: 22744547
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment for 18 hours/day
Study: 22744547
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment for 21 hours/day
Study: 22744547
Drug: Brace treatment
Normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brace treatment for 23 hours/day
Study: 12889696
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (no-gel control)
Study: 10550566
Drug: Etoposide orally
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide orally at 50 mg daily and cyclophosphamide orally at 50 mg daily (first cohort)
Study: 10550566
Drug: Etoposide orally
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide orally at 50 mg twice daily and cyclophosphamide orally at 50 mg twice daily (second cohort)
Study: 8889904
Drug: Dirithromycin 500
Normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dirithromycin 500 mg orally once daily
Study: 8889904
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base 250 mg orally four times daily
Study: 1478125
Drug: Captopril (4-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (4-week treatment)
Study: 1478125
Drug: Captopril (3-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (3-day treatment)
Study: 6362830
Drug: High-dose DTIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DTIC plus actinomycin D
Study: 6362830
Drug: High-dose DTIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DTIC plus actinomycin D (with prior disease-free interval > 6 months)
Study: 6362830
Drug: Immunotherapy limb
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy limb (BHD plus levamisole)
Study: 29469022
Drug: GNB3 non-risk
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: GNB3 non-risk CC homozygotes
Study: 21968714
Drug: Morphine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine bolus
Study: 16198334
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (local and rectal insufflation of the gas)
Study: 16198334
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (topical and systemic)
Study: 12195347
Drug: HAART plus
Normalized name: Tri-Heart Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART plus low-dose prolonged intermittent interleukin (IL)-2 (n=12)
Study: 10363339
Drug: Statistical model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical model examining treatment efficacy in randomized phase III trials with varying alpha levels and sample sizes.
Study: 131139
Drug: Thymoxamine or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoxamine or cromolyn sodium inhalation
Study: 31671060
Drug: SVG-DES (Drug-Eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVG-DES (Drug-Eluting Stent)
Study: 27815344
Drug: SVG-MT (Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVG-MT (Medical Treatment)
Study: 15721027
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (0.625 mg/day of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate)
Study: 15721027
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins (400 IU of Vitamin E and 500 mg of Vitamin C twice daily)
Study: 15721027
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for hormone therapy
Study: 12893194
Drug: Amifostine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (500 mg/m(2)/day days 1‐5) with Topotecan (1.25 mg/m(2)/day days 1‐5)
Study: 12893194
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m(2)/day days 1‐5)
Study: 1752117
Drug: Bradykinin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin (various doses)
Study: 6279061
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of delta 9-tetrahydrocannabinol (THC)
Study: 25023784
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (30 mg/day of elemental iron for 12 weeks)
Study: 25023784
Drug: Iron bis-glycinate
Normalized name: prenatal vitamin no.86/iron bis-glycinate/folic acid 32 mg-1,000 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron bis-glycinate chelate (30 mg/day of elemental iron for 12 weeks)
Study: 22180580
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine replacement therapy (15 mg for 8 weeks)
Study: 18665187
Drug: Quality-of-life diagnosis
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality-of-life diagnosis and therapy (QoL system) implemented for breast cancer patients.
Study: 17132382
Drug: treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment protocol based on a formalised expert opinion
Study: 11095656
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate sodium concentration (L-Na(D))
Study: 29411722
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg gabapentin tablet (Group G, n = 50)
Study: 29411722
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (Group P, n = 50)
Study: 23262451
Drug: Inhaled MgSO(4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled MgSO(4)
Study: 23262451
Drug: β(2‐)agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: β(2‐)agonist
Study: 23262451
Drug: Inhaled MgSO(4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled MgSO(4) + β(2‐)agonist
Study: 8572664
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of deprenyl and/or 2,000 mg of tocopherol/day
Study: 6261607
Drug: 50% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% glucose (0.5 g/kg/h) and insulin (250 U/1,000 cc) with additional insulin up to 200 U/h, maximum 800 U/10 h; 500 ml 10% crystalline amino acid solution on the 1st postoperative day.
Study: 6261607
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate as postoperative infusion (RL-group).
Study: 31420398
Drug: High-Intensity Treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Treatment (HIT) - behaviour therapy, coaching and pharmacological advice
Study: 25077420
Drug: 20-μg rLP2086
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-μg rLP2086 dose
Study: 25077420
Drug: 60-μg rLP2086
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-μg rLP2086 dose
Study: 17848425
Drug: ISIS 301012
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 301012 50-400 mg administered weekly via subcutaneous injection for 4 weeks
Study: 15250199
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of shenmai and compound danshen injection (SM‐DS) before and after PCI
Study: 12583341
Drug: Usual western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual western medicine (Control)
Study: 7847099
Drug: Flutamide (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (750 mg orally daily)
Study: 1255259
Drug: Squibb Iodotope
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squibb Iodotope Diagnostic capsules
Study: 1255259
Drug: Squibb Iodotope
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squibb Iodotope Oral liquid
Study: 1255259
Drug: Iodotope Oral
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodotope Oral liquid
Study: 31434076
Drug: Bortezomib and
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib and Vorinostat (BV) therapy post-ASCT for 12 cycles (28-day cycles)
Study: 31434076
Drug: Bortezomib and
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib and Vorinostat (BV) therapy post-ASCT
Study: 28515056
Drug: Movement control
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Movement control exercise programme (completed three or more weekly sessions)
Study: 30099268
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg) infusion over 40 min
Study: 21807250
Drug: Tiotropium (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (5 μg daily)
Study: 16452355
Drug: Hydrocortisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (1 mg/kg every 8 hours for 5 days)
Study: 11375843
Drug: Tramadol (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (initial dose 100 mg, can increase to 200 mg)
Study: 11375843
Drug: Morphine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (initial dose 5 mg for body weight ≤ 70 kg or 10 mg for body weight > 70 kg, can increase to 15 or 20 mg)
Study: 31009097
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy without ARS (Control)
Study: 23679347
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide 200 μg BID
Study: 27215749
Drug: Aclidinium bromide
Normalized name: Aclidinium Bromide
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aclidinium bromide 400 μg BID
Study: 22050796
Drug: Propofol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0 mg/kg at 3.3 mg/sec after normal saline pretreatment
Study: 22050796
Drug: Propofol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0 mg/kg at 3.3 mg/sec after lidocaine 0.5 mg/kg pretreatment
Study: 22050796
Drug: Propofol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0 mg/kg at 3.3 mg/sec after lidocaine 1.0 mg/kg pretreatment
Study: 22050796
Drug: Propofol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0 mg/kg at 50 mg/sec after normal saline pretreatment
Study: 16517330
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg) and succinylcholine (1 mg/kg)
Study: 16517330
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg) and rocuronium (1 mg/kg)
Study: 16517330
Drug: Remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1 microg/kg) and succinylcholine (1 mg/kg)
Study: 16517330
Drug: Remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1 microg/kg) and rocuronium (1 mg/kg)
Study: 15052769
Drug: Percutaneous estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous estradiol gel combined with micronized progesterone (MP) or medroxyprogesterone acetate (MPA) for 25 days per month
Study: 9553982
Drug: Cetirizine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (active treatment)
Study: 8463453
Drug: 4 or
Normalized name: Dex4 Orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 or 8 mg of sublingual buprenorphine for 21 days
Study: 8463453
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of cocaine (30 mg intravenously) and morphine (10 mg intravenously)
Study: 8463453
Drug: Daily maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily maintenance on buprenorphine
Study: 3710059
Drug: Oleic acid
Normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oleic acid (4.3 g/100 ml)
Study: 24573909
Drug: Electronic containers
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic containers for medication
Study: 24573909
Drug: Standard packaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard packaging for medication
Study: 21756152
Drug: Non-ablative fractional
Normalized name: OMIDUBICEL NON-CULTURED FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative fractional laser therapy (FLT) combined with intermittent daily topical bleaching (5 treatments)
Study: 21756152
Drug: Intermittent regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent regimen of topical bleaching alone
Study: 17373163
Drug: 3-msec alexandrite
Normalized name: Senna alexandrina seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-msec alexandrite laser treatment with fluences between 8 and 32 J/cm2
Study: 17373163
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid (TCS) cream (betamethasone dipropionate)
Study: 17373163
Drug: 3-msec alexandrite
Normalized name: Senna alexandrina seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-msec alexandrite laser treatment
Study: 16115312
Drug: Task-based, community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-based, community oriented teaching model in family medicine (experimental model)
Study: 12381083
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of vitamin C
Study: 12381083
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with a history of KD (no gamma globulin treatment)
Study: 11067699
Drug: Community-based educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based educational intervention for urinary incontinence (specific details on dosage and duration not available)
Study: 8986207
Drug: Low alcohol
Normalized name: Low alcohol beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low alcohol dose (0.48 g/kg/LBM)
Study: 8986207
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol dose (0.72 g/kg/LBM)
Study: 1336131
Drug: LMWH/DHE (low-molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH/DHE (low-molecular weight heparin 1,500 U-aPTT plus dihydroergotamine 0.5 mg, once a day)
Study: 1336131
Drug: HDHE (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDHE (sodium heparin 5,000 U plus dihydroergotamine 0.5 mg, twice a day)
Study: 6725660
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PUVA and UVB
Study: 6725660
Drug: Cumulative doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative doses of PUVA and UVB
Study: 25183657
Drug: Cholecalciferol therapy
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol therapy (50,000 IU twice weekly)
Study: 19778914
Drug: Intranasal HC
Normalized name: Casporyn HC
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal HC gp-39 (30, 150, 300, or 600 microg, once a week)
Study: 12414853
Drug: Oral DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DHEA (50 mg/d)
Study: 12414853
Drug: Conventional hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional hormonal replacement therapy (HRT) (20 micro g ethinyl estradiol/0.1 mg levonorgestrel)
Study: 8565604
Drug: 0.75 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 percent metronidazole gel applied twice daily to the right side of the face
Study: 8565604
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent permethrin cream applied daily to the left side of the face
Study: 8565604
Drug: 0.75 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 percent metronidazole gel
Study: 8565604
Drug: 5 percent
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Lidocaine 5 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 percent permethrin cream
Study: 21482950
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (0.5 mg/day)
Study: 15644830
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Budesonide Inhalation Suspension (BIS)
Study: 15644830
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg Budesonide Inhalation Suspension (BIS)
Study: 29967649
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (8 weeks, twice weekly)
Study: 14557456
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity measured with the euglycemic, hyperinsulinemic clamp
Study: 14557456
Drug: Insulin secretion
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin secretion measured as the acute response to iv arginine (5 g)
Study: 30759132
Drug: Vi-PS vaccine
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-PS vaccine